Efficient Delivery of Dharmacon *SMART*pool® siRNA Reagents in Hard-To-Transfect Cell Lines Using amaxa NUCLEOFECTOR® 96-well Shuttle® System

Thermo SCIENTIFIC

amaxa biosystems

Introduction

siRNA-mediated gene knockdown is a powerful tool that has been used to identify gene function and elucidate biological pathways. Successful siRNA experiments involving knockdown of individual genes or collections of gene targets require efficient delivery of highly functional and specific siRNA molecules into appropriate cells.

While lipid-mediated transfection is a common approach for siRNA delivery, many cell types, including suspension cell lines and primary cells, are not compatible with this technology. These limitations prevent analysis of more biologically-relevant cell types and confines studies to transformed, adherent cell lines that often exhibit phenotypic and genetic alterations after extended periods of culturing. In addition, several of the lipid delivery reagents can cause cytotoxicity and are capable of inducing a potent interferon response.[1] These unintended phenotypes can significantly affect experimental outcomes and drastically interfere with the understanding of a gene's function.

The combination of Dharmacon *SMART*pool® siRNA reagents with amaxa NUCLEOFECTOR® Technology overcomes the limitations associated with lipid reagent-mediated transfection. The technology is optimized for transfection of hard-to-transfect cell types (in particular, primary and non-adherent cell lines) and can be linked to high-throughput applications using the amaxa NUCLEOFECTOR® 96-well Shuttle® System.

In this Technical Note, Dharmacon and amaxa technologies (Box 1) were applied to Jurkat cells (clone E6-1, ATCC® TIB-152™) with the aim of performing future siRNA library screens. Jurkat cells are derived from a human acute T-cell leukemia line and are used extensively in the study of T cell signaling and cancer drug development. As with any suspension cell line, Jurkat cells are hard to transfect using reagent-mediated delivery (Figure 1).



Figure 1. Lipid-mediated transfection of Jurkat cells is ineffective. Jurkat cells were transfected with 100nM GAPDH siRNA using various lipid-based reagents, Dharma*FECT*® 1, 2 and 4 (DF1, DF2, and DF4) are from Dharmacon, Inc., while Lipofectamine™ 2000 (LF2000) is from Invitrogen. Cell viability was determined 24 hours post-transfection using the CellTiter-Blue™ assay (Promega) and normalized to untreated cells. GAPDH mRNA levels were analyzed 24 hours post-transfection by the QuantiGene® branched-DNA assay (Panomics) and normalized to si*CONTROL*® Non-Targeting siRNA #1 (Dharmacon).

Dharmacon - Innovators in RNAi Technologies

- Predesigned, guaranteed si*GENOME*® siRNA products to target every human, mouse, and rat gene in RefSeq database
- Next-generation ON-TARGET*plus*™ siRNA reagents reduce off-targets effects by up to 90% for highly accurate results
- All si*GENOME*® siRNA products available as individual siRNA or *SMART*pool® reagents for maximum experimental flexibility
- si*ARRAY*® siRNA Libraries grouped by pathway or gene ontology for high quality, efficient RNAi screens
- Validated si*CONTROL*® products to ensure experimental reproducibility and silencing specificity

amaxa - Leading Transfection Technology

- Non-viral NUCLEOFECTOR® Technology for transfection of hard-to-transfect cell types, such as suspension cell lines and primary cells
- Up to 99% transfection efficiency with siRNA duplexes, even in suspension cells
- Tested for high viability and maintenance of functionality
- Optimized protocols for hundreds of cell lines and primary cells (see www.amaxa.com/celldatabase)
- Proven for siRNA applications with more than 100 publications
- Efficient co-transfection of different substrates such as plasmid DNA and siRNA duplexes, e.g. for rescue experiments
- NUCLEOFECTOR® 96-well Shuttle® System for high-throughput applications such as siRNA library screening

Box 1. Signature Dharmacon and amaxa technologies.

Critical parameters for successful siRNA experiments

Prior to beginning siRNA experiments using nucleofection®, multiple parameters associated with experimental design need to be optimized. In particular, the 1) nucleofection® conditions (i.e. Nucleofector® Solution and program), 2) appropriate controls, and 3) the most efficacious siRNA concentration and 4) the time point of analysis need to be determined. In addition, identifying the best readout assay for your particular application (i.e. mRNA, protein or phenotypic analysis) is critical. Each of these steps are outlined in Figure 2 and described in detail below.

Optimized programs for siRNA delivery with the NUCLEOFECTOR® 96-well Shuttle®

amaxa provides ready-to-use cell-type specific kits and protocols for a large number of primary cells and cell lines. These detailed protocols can be used in conjunction with either the standard NUCLEOFECTOR® or the NUCLEOFECTOR® 96-well Shuttle® System and are applicable for delivery of any kind of nucleic acid substrate (DNA vectors, ssRNA, siRNA reagents) without any need for further optimization. The constantly growing list of delivery conditions (currently available for over 500 cell types) is referenced in amaxa's cell database (www.amaxa.com).

The 96-well nucleofection® protocol for Jurkat clone E6-1 (ATCC® TIB-152™) recommends the 96-CL-120 program and 96-well Nucleofector® Solution SE for efficient delivery of siRNAs. We have demonstrated that co-transfection of the ON-TARGET*plus*™ *SMART*pool® siRNA reagent targeting maxGFP™ with pmaxGFP™ plasmid (amaxa) results in substantial knockdown of maxGFP™ protein (see Box 2).



Figure 2. Flowchart for successful siRNA Experiments

siRNA duplexes have been shown to be delivered at even greater efficiencies than plasmids. [2,3]

Similarly, co-transfection of a functional siRNA with a plasmid expressing a functional version of the target gene that is resistant to the siRNA can be performed with nucleofection® to prove specificity of the RNAi phenotype (rescue experiments).

Identification of Appropriate Experimental Controls

To ensure that the conclusions drawn from siRNA experiments are accurate, it is necessary to include the appropriate experimental controls. Dharmacon and amaxa scientists recommend including at least four types of experimental controls in every RNAi experiment: positive and negative control samples, an untreated control sample, and a mock-treated control sample. These controls are described here and should be included in all parametric testing along with the siRNA targeting the gene(s) of interest. Dharmacon offers a complete portfolio of both positive and negative control siRNAs in the si*CONTROL*® line of siRNA control reagents. Parallel testing of multiple controls under several conditions can be easily performed using the 96-well Shuttle® System.

1) Positive control: This should be a validated siRNA pool or individual siRNA targeting a well-characterized housekeeping gene, such as cyclophilin B (also known as PPIB), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), or Lamin. A good positive control reagent targeting a well-expressed but non-essential gene is useful for establishing experimental parameters without affecting cellular viability and can also be used as negative control that is unassociated with any particular pathway under study (i.e., it fails to generate a observable phenotype in the assay being employed).

2) Negative control: Negative siRNA control reagents are bioinformatically designed to have no known target in the cell line of choice. These reagents are important for distinguishing sequence-specific silencing from sequence-independent effects that are associated with the delivery of siRNA into the cell.

Such sequence independent effects can include toxicity resulting from transfection in conjunction with nucleic acid delivery or hypersensitivity to introduction of double stranded RNA. Investigators are encouraged to test multiple candidates in their own experimental systems to empirically confirm that the negative controls do not result in any observable and unintended off-target effects.[4,5] Taking this need into account, Dharmacon offers a comprehensive portfolio of multiple negative controls, including the ON-TARGET*plus*™ Non-Targeting Controls, which have been confirmed by microarray analysis to have little to no off-target signature in HeLa cells.



Visual Assessment of Nucleofection® Efficiency with pmaxGFP™

Co-transfection of plasmid in conjunction with siRNA allows for a straightforward analysis of siRNA-mediated gene knockdown. Transfection of pmaxGFP™ alone provides a visual indication of transfection efficiency. Co-transfection of pmaxGFP™ together with Dharmacon ON-TARGET*plus*™ *SMART*pool® siRNA reagent specifically targeting pmaxGFP™ provides a rapid and simple assessment of siRNA-mediated knockdown of maxGFP™.

Box 2. Efficient co-transfection of plasmid and siRNA in Jurkat (clone E6-1, ATCC® TIB-152™) leads to significant down-regulation of maxGFP™ protein. Images were taken 24 hours post-nucleofection® of either pmaxGFP™ plasmid alone or plasmid together with the ON-TARGET*plus*™ *SMART*pool® siRNA reagent targeting maxGFP™. Cells were stained with the nuclear dye Hoechst.

3) Untreated transfection control: The untreated control sample is comprised of cells that have neither been treated with siRNA nor subjected to the transfection process. This control serves as an indicator of baseline cellular activity to which all other conditions can be compared.

4) Mock-treated control: The mock-treated control sample is one in which the cells are subjected to the transfection procedure in the absence of siRNA. In the case of nucleofection®, the cells would be exposed to the NUCLEOFECTOR® Solution and subjected to the nucleofection® procedure in the absence of siRNA. The analysis of mock-treated cells will indicate whether the transfection process results in cytotoxicity or other non-specific effects.

Identifying optimal effective siRNA reagent concentrations

When performing siRNA-mediated knockdown experiments it is advisable to conduct a dose-response (concentration) analysis to determine the minimum siRNA concentration necessary for sufficient target knockdown. For nucleofection® in the 96-well Shuttle®, the optimal siRNA concentration can range from 0.04 – 40 pmol (2 nM up to 2 µM), depending on multiple factors such as the cell type, and the half-life of the mRNA and/or protein of the gene target.

In the context of our optimization studies with Jurkat cells, Figure 3 shows that even the lowest siRNA concentration tested (0.5 pmol, 25 nM) reduces target gene (GAPDH) transcript levels by >75% with only small effects on cellular viability. Nucleofection® of greater amounts of siRNA confirms that maximal silencing is achieved at 5 pmol (250 nM) and that transfection at these or higher siRNA levels has no additional effects on cell viability.

Optimization of Read-out Assay(s)

Determining optimal analysis time points

As the stability and half-life of various mRNAs and their protein products varies, it is important to empirically determine the best time points for assessing target knockdown. For example, it has been documented that in mammalian cells, mRNA half-life can range from minutes to days[6] while the T1/2 of protein products can range from less than a few minutes to several days. Taking this into consideration, the experimental design should allow sufficient time for the siRNA to associate with RISC and deplete mRNA/protein concentrations to desired levels.

In general, the recommended time course ranges are 12 to 72 hours (to deplete target mRNA) and 24 to 96 hours to adequately knockdown target proteins and assess phenotypic outcomes. For GAPDH mRNA levels (half-life, 8 hours[8]) in Jurkats, 24 hours post-nucleofection® was the optimal time point for measuring knockdown (data not shown).



Figure 3. Effect of *SMART*pool® siRNA reagent concentration on GAPDH mRNA levels and cell viability in Jurkat cells clone E6-1 (ATCC® TIB-152™). Cells were nucleofected with various amounts of GAPDH *SMART*pool® siRNA reagent using the 96-well Shuttle® with program 96-CL-120. The negative control sample is the Dharmacon si*CONTROL*® Non-Targeting siRNA Pool. Cell viability was determined 48 hours post-transfection using the CellTiter-Blue™ assay (Promega) and normalized to untreated cells. GAPDH mRNA levels were analyzed 24 hours post-transfection by the QuantiGene® branched-DNA assay (Panomics) and normalized to si*CONTROL*® Non-Targeting siRNA #1 (Dharmacon).

Selecting appropriate phenotypic read-outs

A variety of detection assays may be used to assess cell viability, mRNA levels, and associated phenotypes during the optimization and implementation of a siRNA experiment. Establishing robust assays for RNAi is important for meaningful results. Moreover, multiparametric measurements through the use of several complementary phenotypic assays are particularly helpful in interpreting biological results and performing hit stratification[5].

We chose a well-defined and robust assay set for our experimentation using the NUCLEOFECTOR® 96-well Shuttle® System: the CellTiter-Blue™ assay (Promega) to indicate cell viability and the Apo-ONE® assay (Promega) to monitor apoptosis (caspase 3/7 activity). The QuantiGene® branched DNA assay (Panomics) was utilized to quantitate transcript levels and correlate target knockdown with biological phenotype. Owing to the high-throughput format, the NUCLEOFECTOR® 96-well Shuttle® System facilitates determination of optimal parameters for each of these assays by allowing systematic and parallel testing of several targets and controls under multiple conditions.

To optimize assay conditions, Jurkat cells were nucleofected with a *SMART*pool® siRNA reagent targeting Polo-like kinase 1 (PLK-1). PLK-1 is a key regulator of mitotic progression in mammalian cells and the knockdown of PLK1 is known to induce apoptosis in cancer cells.[7-9] As such, down-regulation of PLK-1 is expected to decrease cell viability and increase caspase 3/7 activity. Initial experiments identified 24 hours post-nucleofection® as optimal for measuring PLK-1 mRNA levels and 48 hours for viability and apoptotic measurements (data not shown).

Figures 4A, B and C demonstrate dose-dependent decreases in transcript levels and correlation with biological phenotype, cell viability and caspase 3/7 activity, respectively. The experiment shows that 5 pmol (250 nM) of siRNA is sufficient to silence ~75% of PLK-1 message and demonstrate a loss in viability and rise in apoptotic activity. Cells nucleofected with GAPDH siRNA (20 pmol, 1 μM) showed similar viability and cellular caspase activity as si*CONTROL*® treated cells. While this knockdown of PLK-1 confirms effects described in the literature, it also serves to define experimental parameters for future siRNA screens using PLK-1 as a positive control for cell viability and caspase 3/7 activity in Jurkat cells.

Conclusions

The combination of the highly functional Dharmacon si*GENOME*® siRNA reagents and the amaxa NUCLEOFECTOR® Technology provides a unique and powerful method for delivering *SMART*pool® siRNA reagents and si*ARRAY*® siRNA libraries into cells that have been considered intractable to lipid reagent-based transfection methods. The NUCLEOFECTOR® 96-well Shuttle® System now expands the technology to large-scale screens by expediting assay optimization and enabling high-throughput siRNA transfection in cell lines that previously have been inaccessible.

References

1. Marques JT and Williams RG (2005) Nat Biotechnol 23(11):1399-405.
2. Shimba S et al. (2005) Proc Natl Acad Sci 102: 12071-12076.
3. Chiu YL et al. (2005) Nature 435: 108-114.
4. Echeverri CJ and Perrimon N (2006) Nat Rev Genet 7:373-84.
5. Echeverri et al. (2006) Nat Methods 3 (10): 777-9.
6. Ross J (1995) Microbiol Rev 59:423-50
7. Spänkuch-Schmitt B et al. (2002). J Natl Cancer Inst 94(24):1863-77.
8. Liu and Erikson (2003) Proc Natl Acad Sci 100:5789-94.
9. Reagan-Shaw S and Ahmad N (2005). FASEB J 19(11):611-3.



Figure 4. Effect of siRNA concentration on PLK-1 mRNA levels (A), induced cell loss (B) and caspase activity (C) in Jurkat clone E6-1 (ATCC® TIB-152™). Cells were nucleofected with various siRNA amounts using the 96-well Shuttle® with program 96-CL-120. PLK1mRNA levels were determined 24 hours post transfection by branched-DNA (Panomics) and normalized to si*CONTROL*® Non-Targeting siRNA #1 (Dharmacon). 48 hours post transfection, cell viability was determined by the CellTiter-Blue™ assay (Promega) and normalized to untreated cells, while caspase activity was determined by the Apo-ONE® (Promega) assay and normalized to cell number and si*CONTROL*® Non-Targeting siRNA #1 (Dharmacon)

The product(s) described herein ("Products") are protected by patents, pending patents and other intellectual property owned or licensed by Dharmacon Inc. as set forth in Dharmacon's Terms and Conditions (found at www.Dharmacon.com or included with the Products when sold). By using the Product(s), users accept the Terms and Conditions, which expressly govern all use of the Product(s). The Product(s) are intended solely for research use and not for diagnostic, clinical or therapeutic uses. Dharmacon's registered and common law trademarks may be found at www.dharmacon.com. © 2006 Dharmacon Inc. All Rights Reserved. Reproduction, distribution or making of derivative works only allowed with permission from Dharmacon. The following are registered trademarks of Dharmacon, Inc.: Dharmacon, the Blue Mountain logo, si*CONTROL*, si*GENOME*, Dharm*FECT*, *SMART*pool. The following is a trademark of Dharmacon, Inc,: ON-TARGET*plus*.

The Nucleofector® Technology, comprising Nucleofection® Process, Nucleofector® Device, Nucleofector® Solutions, Nucleofector® 96-well Shuttle® System and 96-well Nucleocuvette™ plates and modules are covered by patent and/or patent pending rights owned by amaxa GmbH.amaxa, nucleofection, Nucleofector, maxGFP, 96-well Shuttle and Nucleocuvette are either registered trademarks or trademarks of amaxa GmbH in the U.S. and/or Germany and/or other countries..
ATCC® and the ATCC Catalog Marks are trademarks of ATCC used under License.
Apo-ONE® and CellTiter-Blue™ are registered trademarks or trademarks of Promega Corporation in the U.S. and/or other countries.
Other product and company names mentioned herein are the trademarks of their respective owners.
© 2006 amaxa GmbH. All Rights Reserved.

WTA-1003_03_2007